Blood Thinner Tablets Versus Heparin Injections to Prevent Clots in Blood Cancers
Compares apixaban, rivaroxaban and heparin for preventing blood clots in adults with blood cancers.
Plain-language title generated from the registry record
Registry title: Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
Key facts
- Where
- Gdansk, PolandSee the site
Where in Poland
- Department of Haematology & TransplantologyGdansk, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical University of Gdansk
- Trial code
- NCT07270263
- Record updated
- 26 December 2025
- Original description
This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological malignancies. Eligible participants will be randomized to receive reduced-dose apixaban, reduced-dose rivaroxaban, or standard-dose LMWH. The primary objective is to evaluate the incidence of venous thromboembolism during a 6-month follow-up period. Secondary objectives include assessment of bleeding complications, overall survival, and treatment adherence. The results of this study may provide evidence for safer and more convenient thromboprophylaxis strategies in patients with blood cancers.Read full original descriptionShow less
Efficacy and Safety of Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies: A Prospective Randomized Study
This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological malignancies. Eligible participants will be randomized to receive reduced-dose apixaban, reduced-dose rivaroxaban, or standard-dose LMWH. The primary objective is to evaluate the incidence of venous thromboembolism during a 6-month follow-up period. Secondary objectives include assessment of bleeding complications, overall survival, and treatment adherence. The results of this study may provide evidence for safer and more convenient thromboprophylaxis strategies in patients with blood cancers.
Inclusion: Active hematologic malignancy at the time of initiation of systemic therapy, including multiple myeloma, myeloproliferative neoplasm, lymphoma or other hematologic cancer with a Khorana score ≥ 2 points (intermediate or high risk of venous thromboembolism, VTE); Use of anticoagulant agents for primary thromboprophylaxis, including direct oral anticoagulants (DOACs) at reduced doses (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) or low-molecular-weight heparin (LMWH) (enoxaparin 40 mg subcutaneously once daily).
Exclusion: Anticipated significant drug-drug interactions between DOACs and anticancer agents; Major bleeding within the last month (including gastrointestinal or intracranial bleeding); Active major bleeding; History of mechanical heart valve or severe mitral stenosis; Acute coronary syndrome or ischemic stroke within the last 6 months; Known antiphospholipid syndrome (APS); Hemoglobin concentration < 8 g/dL; Thrombocytopenia with platelet count <30 × 10⁹/L; Estimated glomerular filtration rate (eGFR) < 25 mL/min; Hepatic impairment (ALT ≥ 3× upper limit of normal or bilirubin ≥ 2× upper limit of normal); ECOG performance status of 3 or 4; Expected survival <6 months.